SCHEMBL4675312

SCHEMBL4675312

O=C(O)/C(O)=C/C(=O)c1[nH]ccc1Cc1ccncc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
TSHR P16473 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
PNP P00491 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PLA2G7 Q13093 1/20 0.31
GRK2 P25098 1/20 0.31
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30
TBXAS1 P24557 1/20 0.30
GPR52 Q9Y2T5 1/20 0.30
GLA P06280 1/20 0.30
KDM6B O15054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675317 1.00 CYP17A1 (0.35) CYP17A1CYP11B1CYP11B2HDAC1HDAC6
SCHEMBL4675711 0.87 CYP1A2 (0.38) CYP3A4SMN1; SMN2
SCHEMBL4675707 0.87 CYP1A2 (0.38) CYP3A4SMN1; SMN2
SCHEMBL4678128 0.84 HTR6 (0.35) TSHRHRH3CYP3A4
SCHEMBL4672222 0.84 SRD5A2 (0.37) MAPTSMN1; SMN2PDE3BPDE3A
SCHEMBL4673320 0.84 CTBP2 (0.34) MAPT
SCHEMBL4672228 0.84 SRD5A2 (0.37) MAPTSMN1; SMN2PDE3BPDE3A
SCHEMBL4673314 0.84 CTBP2 (0.34) MAPT
SCHEMBL4678126 0.84 HTR6 (0.35) TSHRHRH3CYP3A4
SCHEMBL4677900 0.82 KMT2A (0.45) TSHRMAPTSMN1; SMN2TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CYP17A1 89/4885CYP11B1 63/4885CYP11B2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.